LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -3.2% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 4 | 0 | 1.58M | $1.81B | n/a | n/a |
| Q2 2026 | 193 | +4 | 672.02M | $805.16B | +6 | −1 |
| Q1 2026 | 191 | -3 | 666.59M | $613.20B | +1 | −5 |
| Q4 2025 | 193 | +2 | 707.04M | $758.81B | +3 | n/a |
| Q3 2025 | 27 | -3 | 329.88M | $251.63B | +2 | −6 |
| Q2 2025 | 28 | -1 | 307.45M | $239.60B | +2 | −3 |
| Q1 2025 | 26 | 0 | 140.32M | $115.83B | +1 | −1 |
| Q4 2024 | 26 | +1 | 145.00M | $111.91B | +3 | −2 |
| Q3 2024 | 24 | +2 | 109.89M | $97.29B | +2 | n/a |
| Q2 2024 | 22 | n/a | 112.43M | $101.75B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 34.44M | +0.4% | $28.44B | 1.2% | ▲ Add | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 19.13M | -8.3% | $15.80B | 2.0% | ▼ Trim | 4 | SEC ↗ ×2 |
| 3 | Geode Capital Management ✦ (passive) | 18.53M | +6.6% | $15.25B | 1.2% | ▲ Add | 4 | SEC ↗ ×2 |
| 4 | Capital World Investors ✦ | 18.38M | -6.0% | $15.18B | 2.5% | ▼ Trim | 4 | SEC ↗ |
| 5 | PRIMECAP Management ✦ | 14.78M | -11.8% | $12.21B | 10.1% | ▼ Trim | 4 | SEC ↗ |
| 6 | Wellington Management ✦ | 12.71M | +0.7% | $10.50B | 2.0% | ▲ Add | 4 | SEC ↗ ×9 |
| 7 | Norges Bank ✦ (passive) | 11.00M | +1.0% | $9.08B | 1.3% | ▲ Add | 4 | SEC ↗ |
| 8 | Fisher Asset Management ✦ | 5.44M | +3.9% | $4.49B | 1.9% | ▲ Add | 4 | SEC ↗ |
| 9 | Tiger Global Management ✦ | 1.33M | +1.9% | $1.10B | 4.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Adage Capital Partners ✦ | 741.72K | +1.2% | $612.60M | 1.1% | ▲ Add | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 681.01K | -15.0% | $562.46M | 0.6% | ▼ Trim | 4 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 573.33K | -53.8% | $473.52M | 0.6% | ▼ Trim | 4 | SEC ↗ ×2 |
| 13 | AQR Capital Management ✦ | 567.50K | -11.9% | $456.15M | 0.5% | ▼ Trim | 4 | SEC ↗ ×7 |
| 14 | Lone Pine Capital ✦ | 551.83K | -29.5% | $455.76M | 4.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Citadel Advisors ✦ | 477.78K | -21.8% | $394.60M | 0.4% | ▼ Trim | 4 | SEC ↗ ×2 |
| 16 | Marshall Wace ✦ | 419.50K | +7.9% | $346.47M | 0.5% | ▲ Add | 4 | SEC ↗ ×4 |
| 17 | Coatue Management ✦ | 183.72K | -14.1% | $151.74M | 0.7% | ▼ Trim | 4 | SEC ↗ ×5 |
| 18 | Renaissance Technologies ✦ | 96.31K | +78.0% | $79.55M | 0.1% | ▲ Add | 3 | SEC ↗ |
| 19 | Duquesne Family Office ✦ | 94.83K | +52.5% | $78.32M | 2.6% | ▲ Add | 2 | SEC ↗ |
| 20 | Point72 Asset Management ✦ | 54.77K | New | $45.24M | 0.1% | New | 1 | SEC ↗ |
| 21 | Dodge & Cox ✦ | 45.09K | +0.7% | $37.24M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 22 | Arrowstreet Capital ✦ | 41.41K | +178.9% | $34.20M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 23 | GAMCO Investors ✦ | 30.07K | -10.3% | $24.84M | 0.3% | ▼ Trim | 4 | SEC ↗ |
| 24 | Two Sigma Investments ✦ | 15.73K | -95.1% | $12.99M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 25 | Gotham Asset Management ✦ | 7.55K | +30.6% | $6.23M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 26 | Bridgewater Associates ✦ | 2.75K | -96.7% | $2.27M | 0.0% | ▼ Trim | 4 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Point72 Asset Management | $45.24M | 0.1% |
Exited
| Soros Fund Management | $25.97M | was 0.7% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 4,323 holders, 762.84M shares, $674.93B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.50K sh · $7.64M
Officer · 2.00K sh · $2.37M
Officer · 5.00K sh · $5.95M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology